Press Releases



    • MAR 04 2019

    Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe

    Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034.  This patent covers the composition of matter for ONC206, its di-salt formulation, and its use in the treatment of cancer.

    • FEB 25 2019

    Oncoceutics and the National Cancer Institute Collaborate to Develop ONC206

    Philadelphia, PA (February 22, 2019) – Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health (NIH) involving its imipridone family of anti-cancer compounds. ONC206 has been studied extensively for several years in models of central nervous system cancers, including high grade gliomas as evaluated by the laboratory of Mark